A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population is patients with NASH and F3 fibrosis, between the ages of 18-75.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: liver fibrosis
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 833117

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Brief description of study

Eligibility of study

Find a site